Herpes zoster vaccine GSK1437173A

Herpes Zoster Vaccine GSK1437173A

A vial of Herpes Zoster Vaccine.

The Herpes Zoster Vaccine GSK1437173A is a recombinant, subunit vaccine designed to prevent infection with Herpes Zoster (HZ), also known as shingles. This vaccine targets individuals at risk of developing shingles, a condition caused by the reactivation of the Varicella Zoster Virus (VZV) — the same virus responsible for chickenpox. Unlike live-attenuated vaccines, GSK1437173A contains a specific VZV glycoprotein E (gE), a predominant antigen found in VZV viral particles that plays a crucial role in VZV infection.

Composition and Mechanism

GSK1437173A is composed of VZV glycoprotein E (gE) and includes adjuvants to enhance the immune response. Upon administration, it stimulates the host's immune system to induce a potent and specific immune response, including the production of CD4-positive T-cells and antibodies against VZV gE. This targeted immune response provides protection against shingles by preventing VZV reactivation.

Benefits

• Reduced Risk for Immunocompromised Patients: Since it is a subunit vaccine and does not contain live virus, GSK1437173A minimizes the risk of vaccine-induced herpes zoster in immunocompromised patients.
• Targeted Immune Response: The vaccine specifically enhances immunity against the gE antigen, a key player in VZV pathogenesis, offering focused protection against shingles.
• Long-lasting Protection: Early studies suggest that the immune response induced by GSK1437173A may offer long-lasting protection against shingles, though ongoing research is needed to fully understand the duration of vaccine efficacy.

Comparison with Other Vaccines

GSK1437173A differs from live-attenuated herpes zoster vaccines, which contain a weakened form of the virus. The subunit nature of GSK1437173A offers a safer alternative for individuals with weakened immune systems, providing effective protection without the associated risks of live-attenuated vaccines.

Indications and Usage

The vaccine is recommended for adults aged 50 and over, who are at increased risk for developing shingles and its complications. Specific guidelines and recommendations may vary by region and are subject to updates based on ongoing research and regulatory approvals.

See Also

• Varicella Zoster Virus
• Immunology
• Vaccine
• Immunocompromised patient

External Links

• Centers for Disease Control and Prevention (CDC) - Shingles (Herpes Zoster)
• World Health Organization (WHO) - Herpes Zoster (Shingles)

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia